Education
About Us
Working with TipRanks
Follow Us
GlaxoSmithKline (GB:GSK)
LSE:GSK
GSK Stock Chart & Stats
Day’s Range― - ―
52-Week Range1,282.50p - 1,823.50p
Previous CloseN/A
Volume367.08K
Average Volume (3M)10.11M
Market Cap
£60.01B
Enterprise Value68.32B
Total Cash (Recent Filing)£3.69B
Total Debt (Recent Filing)£16.99B
Price to Earnings (P/E)23.5
Beta0.65
Next Earnings
Apr 30, 2025EPS Estimate
41.3Last Dividend Ex-Date
Feb 20, 2025Dividend Yield4.1%
Share Statistics
EPS (TTM)0.63
Shares Outstanding4,131,272,500
10 Day Avg. Volume10,523,450
30 Day Avg. Volume10,107,409
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.99
Price to Cash Flow (P/CF)15.10
P/FCF Ratio23.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
1,588.33pPrice Target Upside7.65% Upside
Rating ConsensusHold
Number of Analyst Covering12
---
Bulls Say, Bears Say
Bulls Say
Pipeline DevelopmentJemperli has a broad endometrial label and is the only PD1/L1 with significant overall survival in first-line treatment, offering opportunities for combination with other drugs.
Product LaunchThe launch of Nucala for COPD has shown positive results in clinical trials, potentially providing an advantage over competing treatments.
Bears Say
Earnings OutlookGSK is expected to have the worst EPS growth rate from 2026 to 2029 as key franchises mature or decline.
Financial PerformanceDespite significant headwinds, GSK expects sales to grow by MSD and earnings from 6 to 8% at CER.
Market ChallengesThe outlook for GSK's vaccine division is concerning, with expectations of a decline, especially with challenges in the Chinese market.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.10% Insiders
11.26%
Mutual Funds
0.08% Other Institutional Investors
76.07% Public Companies and
Individual Investors
GSK FAQ
What was GlaxoSmithKline’s price range in the past 12 months?
GlaxoSmithKline lowest share price was 1282.50p and its highest was 1823.50p in the past 12 months.
What is GlaxoSmithKline’s market cap?
GlaxoSmithKline’s market cap is £60.01B.
When is GlaxoSmithKline’s upcoming earnings report date?
GlaxoSmithKline’s upcoming earnings report date is Apr 30, 2025 which is in 34 days.
How were GlaxoSmithKline’s earnings last quarter?
GlaxoSmithKline released its earnings results on Feb 05, 2025. The company reported 0.232p earnings per share for the quarter, beating the consensus estimate of 0.198p by 0.034p.
Is GlaxoSmithKline overvalued?
According to Wall Street analysts GlaxoSmithKline’s price is currently Undervalued.
Does GlaxoSmithKline pay dividends?
GlaxoSmithKline pays a Annually dividend of 15.999p which represents an annual dividend yield of 4.1%. See more information on GlaxoSmithKline dividends here
What is GlaxoSmithKline’s EPS estimate?
GlaxoSmithKline’s EPS estimate is 41.3.
How many shares outstanding does GlaxoSmithKline have?
GlaxoSmithKline has 4,131,272,500 shares outstanding.
What happened to GlaxoSmithKline’s price movement after its last earnings report?
GlaxoSmithKline reported an EPS of 0.232p in its last earnings report, beating expectations of 0.198p. Following the earnings report the stock price went up 7.609%.
Which hedge fund is a major shareholder of GlaxoSmithKline?
Currently, no hedge funds are holding shares in GB:GSK
---
GlaxoSmithKline Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
1,588.33p (7.65% Upside)
1,588.33p (7.65% Upside)
Insider Transactions
Sold Shares
Worth £11.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.54%
12-Months-Change
Fundamentals
Return on Equity
19.06%
Trailing 12-Months
Asset Growth
0.78%
Trailing 12-Months
Company Description
GlaxoSmithKline
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
---
GSK Stock 12 Month Forecast
Average Price Target
1,588.33p
▲(7.65% Upside)
Technical Analysis
Best Analysts Covering GSK
1 Year
1 Year Success Rate
15/32 ratings generated profit
1 Year Average Return
+5.76%
reiterated a buy rating 3 months ago
Copying Kerry Holford's trades and holding each position for 1 Year would result in 46.88% of your transactions generating a profit, with an average return of +5.76% per trade.
---